EP0716854A3 - Compositions pour inhiber le récepteur de la neuropeptide Y - Google Patents
Compositions pour inhiber le récepteur de la neuropeptide Y Download PDFInfo
- Publication number
- EP0716854A3 EP0716854A3 EP95307301A EP95307301A EP0716854A3 EP 0716854 A3 EP0716854 A3 EP 0716854A3 EP 95307301 A EP95307301 A EP 95307301A EP 95307301 A EP95307301 A EP 95307301A EP 0716854 A3 EP0716854 A3 EP 0716854A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- receptors
- compositions
- inhibiting neuropeptide
- neuropeptide
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98203285A EP0895781A3 (fr) | 1994-10-20 | 1995-10-13 | Utilisation de benzofuranes, benzothiophénes ou d'indoles pour la fabrication d'un médicament pour le tratement de consitions provoquèes par un excés de tachykinines |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32641294A | 1994-10-20 | 1994-10-20 | |
US08/326,413 US5663192A (en) | 1994-10-20 | 1994-10-20 | Heterocyclic neuropeptide Y receptor antagonists |
US326413 | 1994-10-20 | ||
US326412 | 1994-10-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98203285A Division EP0895781A3 (fr) | 1994-10-20 | 1995-10-13 | Utilisation de benzofuranes, benzothiophénes ou d'indoles pour la fabrication d'un médicament pour le tratement de consitions provoquèes par un excés de tachykinines |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0716854A2 EP0716854A2 (fr) | 1996-06-19 |
EP0716854A3 true EP0716854A3 (fr) | 1996-08-28 |
Family
ID=26985394
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95307301A Withdrawn EP0716854A3 (fr) | 1994-10-20 | 1995-10-13 | Compositions pour inhiber le récepteur de la neuropeptide Y |
EP98203285A Withdrawn EP0895781A3 (fr) | 1994-10-20 | 1995-10-13 | Utilisation de benzofuranes, benzothiophénes ou d'indoles pour la fabrication d'un médicament pour le tratement de consitions provoquèes par un excés de tachykinines |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98203285A Withdrawn EP0895781A3 (fr) | 1994-10-20 | 1995-10-13 | Utilisation de benzofuranes, benzothiophénes ou d'indoles pour la fabrication d'un médicament pour le tratement de consitions provoquèes par un excés de tachykinines |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP0716854A3 (fr) |
AU (1) | AU3953795A (fr) |
IL (1) | IL115613A0 (fr) |
WO (1) | WO1996012489A1 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3953695A (en) * | 1994-10-20 | 1996-05-15 | Eli Lilly And Company | Bicyclic bradykinin receptor antagonists |
US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
US5989920A (en) | 1994-12-02 | 1999-11-23 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5 |
EP0759441A3 (fr) * | 1995-06-30 | 1999-06-30 | Eli Lilly And Company | Procédés de traitement des pathologies associées aux peptides neuropeptide Y |
ZA965346B (en) * | 1995-06-30 | 1997-12-24 | Lilly Co Eli | Methods of treating neuropeptide Y-associated conditions. |
GB9523999D0 (en) | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
IL120724A0 (en) * | 1995-09-01 | 1997-08-14 | Lilly Co Eli | Indolyl neuropeptide Y receptor antagonists |
WO1997020823A2 (fr) * | 1995-12-01 | 1997-06-12 | Novartis Ag | Antagonistes de recepteurs |
AU7692896A (en) * | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
CA2206752A1 (fr) * | 1996-07-02 | 1998-01-02 | George Joseph Cullinan | Composes de benzothiophene,intermediaires, procedes et methodes d'utilisation |
DE69713402T2 (de) | 1996-08-23 | 2002-11-07 | Agouron Pharma | Liganden des neuropeptids y |
FR2754709B1 (fr) | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
EP0927166A1 (fr) * | 1997-02-14 | 1999-07-07 | Bayer Corporation | Amides utilises comme antagonistes du recepteur de npy5 |
US6245817B1 (en) | 1997-02-14 | 2001-06-12 | Bayer Corporation | NPY5 receptor antagonists and methods for using same |
US6048900A (en) * | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
WO1998035957A1 (fr) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Derives amides actifs comme antagonistes selectifs du recepteur du neuropeptide y |
US6713265B1 (en) | 1997-06-04 | 2004-03-30 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
AUPQ100799A0 (en) * | 1999-06-17 | 1999-07-08 | Green Peaks Pty Ltd | Fire barrier panel |
WO2002003988A2 (fr) * | 2000-07-06 | 2002-01-17 | Wyeth | Methodes permettant de traiter de troubles associes au neuropeptide y - |
WO2004098591A2 (fr) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibiteurs de glutaminyl-cyclase |
EP1680120A2 (fr) | 2003-11-03 | 2006-07-19 | Probiodrug AG | Combinaisons utiles au traitement de troubles neuronaux |
CN1918131B (zh) | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶抑制剂 |
WO2008055945A1 (fr) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
SI2091948T1 (sl) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novi inhibitorji glutaminil ciklaze |
EP2481408A3 (fr) | 2007-03-01 | 2013-01-09 | Probiodrug AG | Nouvelle utilisation d'inhibiteurs glutaminyle cyclase |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
AU2010294214B2 (en) | 2009-09-11 | 2015-05-07 | Vivoryon Therapeutics N.V. | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
EP2560953B1 (fr) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibiteurs de glutaminyl cyclase |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
WO2020109546A1 (fr) * | 2018-11-29 | 2020-06-04 | University Of Copenhagen | Traitement de maladies cardiovasculaires |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024273A (en) * | 1974-06-20 | 1977-05-17 | Smithkline Corporation | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
EP0605193A1 (fr) * | 1992-12-22 | 1994-07-06 | Eli Lilly And Company | Utilisation des benzothiophènes pour le traitement de l'hypercholestérolemie |
EP0617030A1 (fr) * | 1993-03-19 | 1994-09-28 | Eli Lilly And Company | Dérivés de sulphonate et carbamate de aroyl-3-benzo(bêta)thiophènes |
EP0659413A2 (fr) * | 1993-12-21 | 1995-06-28 | Eli Lilly And Company | Inhibition de problèmes CNS chez les femmes post-ménopausées |
EP0659411A2 (fr) * | 1993-12-21 | 1995-06-28 | Eli Lilly And Company | Méthode pour augmenter la libido chez les femmes en post-ménopause |
EP0659428A1 (fr) * | 1993-12-21 | 1995-06-28 | Eli Lilly And Company | 2-Phényl-3-azoylbenzothiophènes pour traiter les maladies obsessionelles et de la consommation |
WO1995017382A1 (fr) * | 1993-12-21 | 1995-06-29 | Eli Lilly And Company | Antagonistes non peptidiques des recepteurs des tachykinines |
WO1995017095A1 (fr) * | 1993-12-21 | 1995-06-29 | Eli Lilly And Company | Procedes permettant de traiter ou de prevenir les pathologies associees aux peptides amyloïdogenes |
EP0668075A2 (fr) * | 1993-12-21 | 1995-08-23 | Eli Lilly And Company | Antagonistes de récepteurs tachykiniques de nature non-peptidiques |
-
1995
- 1995-10-13 EP EP95307301A patent/EP0716854A3/fr not_active Withdrawn
- 1995-10-13 IL IL11561395A patent/IL115613A0/xx unknown
- 1995-10-13 WO PCT/US1995/013035 patent/WO1996012489A1/fr active Search and Examination
- 1995-10-13 EP EP98203285A patent/EP0895781A3/fr not_active Withdrawn
- 1995-10-13 AU AU39537/95A patent/AU3953795A/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024273A (en) * | 1974-06-20 | 1977-05-17 | Smithkline Corporation | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
EP0605193A1 (fr) * | 1992-12-22 | 1994-07-06 | Eli Lilly And Company | Utilisation des benzothiophènes pour le traitement de l'hypercholestérolemie |
EP0617030A1 (fr) * | 1993-03-19 | 1994-09-28 | Eli Lilly And Company | Dérivés de sulphonate et carbamate de aroyl-3-benzo(bêta)thiophènes |
EP0659413A2 (fr) * | 1993-12-21 | 1995-06-28 | Eli Lilly And Company | Inhibition de problèmes CNS chez les femmes post-ménopausées |
EP0659411A2 (fr) * | 1993-12-21 | 1995-06-28 | Eli Lilly And Company | Méthode pour augmenter la libido chez les femmes en post-ménopause |
EP0659428A1 (fr) * | 1993-12-21 | 1995-06-28 | Eli Lilly And Company | 2-Phényl-3-azoylbenzothiophènes pour traiter les maladies obsessionelles et de la consommation |
WO1995017382A1 (fr) * | 1993-12-21 | 1995-06-29 | Eli Lilly And Company | Antagonistes non peptidiques des recepteurs des tachykinines |
WO1995017095A1 (fr) * | 1993-12-21 | 1995-06-29 | Eli Lilly And Company | Procedes permettant de traiter ou de prevenir les pathologies associees aux peptides amyloïdogenes |
EP0668075A2 (fr) * | 1993-12-21 | 1995-08-23 | Eli Lilly And Company | Antagonistes de récepteurs tachykiniques de nature non-peptidiques |
Non-Patent Citations (2)
Title |
---|
LARS EDVINSSON ET AL.: "Neuropeptide Y in Sympathetic Co-Transmission: Recent Advances in the Search for Neuropeptide Y Antagonists", PHARMACOL. TOXICOL., vol. 74, no. 4-5, pages 193 - 201, XP002005758 * |
LARS GRUNDEMAR ET AL.: "Neuropeptide Y effector systems: perspectives for drug development", TRENDS PHARMACOL. SCI., vol. 15, no. 4, pages 153 - 159, XP002005759 * |
Also Published As
Publication number | Publication date |
---|---|
EP0895781A3 (fr) | 1999-07-07 |
EP0716854A2 (fr) | 1996-06-19 |
IL115613A0 (en) | 1996-01-19 |
AU3953795A (en) | 1996-05-15 |
WO1996012489A1 (fr) | 1996-05-02 |
EP0895781A2 (fr) | 1999-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0716854A3 (fr) | Compositions pour inhiber le récepteur de la neuropeptide Y | |
EP0791009A4 (fr) | Recepteurs neuropeptidiques y modifies | |
IL120092A0 (en) | Cosmetic compositions containing a neuropeptide Y receptor antagonist | |
ZA957233B (en) | Topically-effective compositions | |
EG20929A (en) | Cleasing compositions | |
GB9408545D0 (en) | Compositions | |
ZA954683B (en) | Synergistic compositions | |
IL127684A0 (en) | Composition for appetite suppression | |
HUP9602943A3 (en) | Composition for inhibiting angiogenesis | |
PL322532A1 (en) | Synergic compositions | |
IL122126A (en) | Synergistic phytomicrobicidal compositions | |
EP1020194A4 (fr) | Compositions d'emulsions de type aqueux | |
EP1015014A4 (fr) | Procedes et compositions pour inhiber l'angiogenese | |
IL119070A0 (en) | Synergistic fungicidal compositions | |
HUT74746A (en) | Pharmaceutical compositions containing p antagonist | |
GB9409543D0 (en) | Compositions | |
GB9716533D0 (en) | Additives for oil compositions | |
GB9502770D0 (en) | Amine-curable compositions | |
ZA94718B (en) | Benzimidazole compositions | |
ZA954709B (en) | Mineral-fiber compositions | |
GB2290299B (en) | Anti-lubricant compositions | |
GB2293376B (en) | Concrete compositions | |
GB2291060B (en) | Cement compositions | |
GB9415453D0 (en) | Anti perspirant compositions | |
GB9416768D0 (en) | Compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951020 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 951020;LV PAYMENT 951020;SI PAYMENT 951020 |
|
RAX | Requested extension states of the european patent have changed |
Free format text: LT PAYMENT 951020;LV PAYMENT 951020;SI PAYMENT 951020 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 951020;LV PAYMENT 951020;SI PAYMENT 951020 |
|
17Q | First examination report despatched |
Effective date: 19970320 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20001002 |